JANX

Janux Therapeutics Inc

May 18 • 04:00PM ET

14.03

+0.14 1.01 %

Healthcare • Biotechnology • USA • Small • NASD

| Held by: XBI VTI IWM VXF IBB IWN SCHA VTWO VHT IWO

Index	RUT	P/E	-	EPS (ttm)	-1.84	Insider Own	8.62%	Shs Outstand	60.87M	Perf Week	-1.41%
Market Cap	855.61M	Forward P/E	-	EPS next Y	-2.74	Insider Trans	-0.46%	Shs Float	55.83M	Perf Month	-11.31%
Enterprise Value	-79.21M	PEG	-	EPS next Q	-0.31	Inst Own	95.17%	Short Float	14.21%	Perf Quarter	6.21%
Income	-114.48M	P/S	62.32	EPS this Y	-2.60%	Inst Trans	-4.64%	Short Ratio	7.95	Perf Half Y	-48.91%
Sales	13.73M	P/B	0.91	EPS next Y	-46.16%	ROA	-11.01%	Short Interest	7.93M	Perf YTD	1.67%
Book/sh	15.47	P/C	0.89	EPS next 5Y	-22.59%	ROE	-11.72%	52W High	35.34 -60.30%	Perf Year	-42.22%
Cash/sh	15.68	P/FCF	-	EPS past 3/5Y	-6.44% -62.26%	ROIC	-11.92%	52W Low	12.12 15.76%	Perf 3Y	11.35%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	5.11% -	Gross Margin	85.59%	Volatility	3.98% 4.25%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-5.77	EPS Y/Y TTM	-35.51%	Oper. Margin	-1143.11%	ATR (14)	0.59	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	17.01	Sales Y/Y TTM	47.10%	Profit Margin	-833.60%	RSI (14)	42.89	Recom	1.58
Dividend Gr. 3/5Y	- -	Current Ratio	17.01	EPS Q/Q	-2.21%	SMA20	-3.65%	Beta	2.55	Target Price	40.35
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-2.73%	Rel Volume	0.72	Prev Close	13.89
Employees	109	LT Debt/Eq	0.02	Earnings	May 07 AMC	SMA200	-26.71%	Avg Volume	997.63K	Price	14.03
IPO	Jun 11, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	29.17% -14.10%	Trades		Volume	725,947	Change	1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-20-26	Downgrade	Barclays	Overweight → Underweight	$14
Apr-15-26	Downgrade	UBS	Buy → Neutral	$15
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Sep-17-25	Initiated	Barclays	Overweight	$47
Sep-10-25	Initiated	Truist	Buy	$100
Sep-10-25	Initiated	Stifel	Buy	$45
Sep-04-25	Initiated	Guggenheim	Buy	$72
Aug-19-25	Initiated	Piper Sandler	Overweight	$42
Jul-11-25	Initiated	Raymond James	Outperform	$65
Dec-03-24	Reiterated	H.C. Wainwright	Buy	$63 → $70
Dec-03-24	Reiterated	BTIG Research	Buy	$82 → $100
Nov-22-24	Initiated	Leerink Partners	Outperform	$79
Oct-24-24	Initiated	UBS	Buy	$69
Sep-06-24	Initiated	Stifel	Buy	$70
May-30-24	Initiated	Scotiabank	Sector Perform	$47
Mar-21-24	Initiated	BTIG Research	Buy	$62
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight	$100
Apr-06-23	Initiated	Wedbush	Outperform	$24
Nov-14-22	Initiated	William Blair	Outperform

Show Previous Ratings

May-07-26 04:01PM	Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights (Business Wire)
Apr-28-26 05:57AM	FDA claims Amgen drug data were manipulated; Erasca slides despite home run results (BioPharma Dive)
Apr-27-26 04:01PM	Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development (Business Wire)
Apr-17-26 06:04AM	Lillys obesity pill off to a strong start; OpenAI debuts new drug discovery tool (BioPharma Dive)
Apr-16-26 04:01PM	Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 (Business Wire)
08:01AM	Loading…
Apr-01-26 08:01AM	Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment (Business Wire)
Mar-02-26 02:56AM	Janux Therapeutics, Inc. (JANX) Commences Patient Dosing of JANX011 in Autoimmune Trial (Insider Monkey)
Feb-26-26 04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (Business Wire)
Feb-19-26 09:59AM	Where is Janux Therapeutics (JANX) Headed According to Analysts? (Insider Monkey)
Feb-17-26 07:00AM	Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 (Business Wire)
Feb-16-26 09:40AM	Wall Street Thinks These 4 Biotech Stocks Will DoubleAt LeastThis Year (24/7 Wall St.)
Feb-03-26 09:55AM	Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High? (Zacks)
Jan-26-26 07:00AM	Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer (Business Wire)
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
Jan-22-26 02:02PM	Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million (Benzinga) +14.09%
01:01PM	Loading…
01:01PM	BMS bets on Januxs novel solid tumour therapy through $850m deal (Pharmaceutical Technology)
07:00AM	Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors (Business Wire)
07:00AM	Bristol Myers buys into Januxs masked T cell engagers (BioPharma Dive)
Dec-27-25 07:43AM	Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) (Insider Monkey)
Dec-23-25 04:05PM	Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study (Business Wire)
Dec-12-25 07:30AM	2 Strong Buy Biotech Stocks With 208% to 329% Upside Potential (Barchart)
Dec-02-25 04:14PM	Janux Therapeutics Craters 53% On Prostate Cancer Update; Is It An 'Overreaction'? (Investor's Business Daily) -53.34% +7.88%
09:53AM	Janux Therapeutics Stock Craters After Positive Cancer Data. Why Its Down 50%. (Barrons.com)
08:30AM	Janux Therapeutics Stock Craters After 'Positive' Cancer Drug Trial Data. Why It's Down 41%. (Barrons.com)
05:15AM	Janux sinks on overreaction to prostate cancer data; RFK Jr. replaces ACIP chair (BioPharma Dive)
Dec-01-25 04:05PM	Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC (Business Wire)
Nov-24-25 08:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC (Business Wire) +9.48%
Nov-16-25 10:13PM	Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program (Insider Monkey)
Nov-06-25 06:10PM	Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.61%
04:01PM	Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
05:53AM	Loading…
Oct-30-25 05:53AM	Wave Life Sciences (WVE) Soars 8.8%: Is Further Upside Left in the Stock? (Zacks)
Oct-29-25 07:46AM	Janux Therapeutics (JANX) Moves 8.8% Higher: Will This Strength Last? (Zacks) -6.55%
07:05AM	GSK (GSK) Q3 Earnings and Revenues Beat Estimates (Zacks)
Oct-20-25 11:08PM	Janux Therapeutics (JANX) Gets Initiated With a Buy Rating at Truist Financial (Insider Monkey)
Oct-10-25 10:06AM	Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Oct-09-25 09:25AM	Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains? (Zacks) +6.82%
Sep-15-25 09:09AM	Truist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PT (Insider Monkey)
Sep-10-25 09:51AM	Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls (The Fly)
Aug-17-25 11:41PM	Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration (Insider Monkey)
Aug-07-25 04:01PM	Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire) -6.62%
Aug-05-25 04:05PM	Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck (Business Wire) +6.65% -5.18%
Jul-24-25 04:05PM	Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day (Business Wire)
Jul-17-25 04:30PM	Janux Therapeutics to Host Virtual R&D Day on July 24, 2025 (Business Wire)
Jul-12-25 09:40AM	CoreWeave initiated, Texas Instruments upgraded: Wall Streets top analyst calls (TipRanks)
Jul-11-25 09:38AM	CoreWeave initiated, Texas Instruments upgraded: Wall Street's top analyst calls (The Fly)
Jun-24-25 05:42PM	JonesTrading Remains Bullish on Janux Therapeutics (JANX) With a $90 Price Target (Insider Monkey)
May-15-25 08:00AM	Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer (Business Wire)
May-08-25 04:01PM	Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
May-06-25 05:30AM	Janux commences Phase Ib studies in trial for prostate cancer treatment (Clinical Trials Arena) -14.27%
May-05-25 10:10AM	Janux Therapeutics, Inc. (JANX): Among Unknown Billionaire Phill Gross' Stock Picks with Huge Upside Potential (Insider Monkey) -9.40%
08:30AM	Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates (Business Wire)
07:58AM	Is Janux Therapeutics, Inc. (JANX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey)
Apr-07-25 05:14PM	Janux Therapeutics: What's My Inflection Point? (Seeking Alpha) -5.39%
Apr-05-25 08:14AM	Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout (Seeking Alpha)
Mar-28-25 10:36AM	Is Janux Therapeutics Inc. (NASDAQ:JANX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? (Insider Monkey)
Mar-26-25 09:40PM	Is Janux Therapeutics, Inc. (NASDAQ:JANX) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
Mar-25-25 10:45AM	Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in March (InsiderMonkey)
Mar-20-25 04:43PM	Is Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy? (InsiderMonkey)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-14-25 06:17PM	WEX, Lamb Weston, and More Stocks See Action From Activist Investors (Barrons.com)
12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Mar-05-25 06:53PM	Janux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending Recently (Insider Monkey) +5.04%
Mar-01-25 10:00AM	Janux Therapeutics price target lowered to $41 from $62 at Scotiabank (TipRanks)
Feb-27-25 04:01PM	Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire)
Feb-24-25 01:07PM	Janux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy Now (Insider Monkey) -6.75%
Jan-24-25 04:01PM	Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer (Business Wire)
Dec-06-24 07:43PM	Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million (Business Wire) -5.14%
Dec-04-24 11:12PM	Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants (Business Wire) +11.65%
06:23PM	Why Janux Therapeutics Crushed the Market Today (Motley Fool)
Dec-03-24 04:07PM	Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride (Investor's Business Daily) +48.98%
04:01PM	Janux Therapeutics Announces Proposed Public Offering (Business Wire)
11:58AM	Janux Rockets 41% in Five Days as Cancer Breakthrough Fuels Market Buzz (GuruFocus.com)
11:20AM	Janux Therapeutics Stock Soars on Prostate Cancer Drug Trial Results (Barrons.com)
10:01AM	Janux Skyrockets: 69% Surge This Morning Leads to 650% Gain in a Year (GuruFocus.com)
09:02AM	Janux, Vir Catapult On 'Unprecedented' Results In Prostate Cancer Patients (Investor's Business Daily)
06:13AM	Janux impresses Wall Street with new prostate cancer drug results (BioPharma Dive)
Dec-02-24 04:30PM	Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC (Business Wire) -11.13%
Nov-25-24 09:00AM	Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies (Business Wire)
Nov-23-24 06:21AM	Janux Therapeutics initiated with an Outperform at Leerink (TipRanks)
Nov-15-24 08:34PM	Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-06-24 04:01PM	Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire)
Nov-01-24 06:33PM	Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-23-24 09:05PM	Paradigm Biocapital Advisors LP Acquires Shares in Janux Therapeutics Inc (GuruFocus.com)
Oct-22-24 09:07PM	RA Capital Management Reduces Stake in Janux Therapeutics (GuruFocus.com)
Oct-07-24 05:08PM	Janux Therapeutics, Inc. (JANX): A Hot Stock to Buy Now (Insider Monkey)
Sep-26-24 07:30PM	Is Janux Therapeutics Inc. (JANX) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-20-24 06:39PM	Lennar, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
Sep-17-24 01:30AM	RA Capital Management L.P. Increases Stake in Janux Therapeutics Inc (GuruFocus.com)
Sep-14-24 07:33PM	Janux Therapeutics, Inc. (JANX): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-13-24 06:10AM	Janux Therapeutics (JANX) Moves 6.5% Higher: Will This Strength Last? (Zacks) +7.48%
Aug-16-24 04:36PM	Southwest Airlines, Rocket Lab USA, and More Stocks See Action From Activist Investors (Barrons.com) +5.08%
Aug-07-24 11:54PM	JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:15PM	Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire)
Jul-22-24 04:01PM	Janux Therapeutics Announces Updates to Board of Directors (Business Wire) +6.80%
Jul-01-24 11:13AM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
Jun-14-24 07:05PM	TruBridge, Evans Bancorp, and More Stocks See Action From Activist Investors (Barrons.com)
May-17-24 04:12PM	Google DeepMind CEO: 'This Is the Next $100 Billion AI Business' (InvestorPlace)
May-09-24 10:26AM	Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb (PR Newswire) -6.19%
May-08-24 09:06AM	Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating (MT Newswires) -9.97%

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

PresidentDr. David Alan Campbell Ph.D.

Chief Scientific OfficerDr. Thomas Diraimondo Ph.D.

Chief Corporate & Business Development OfficerMs. Janeen Doyle

Vice President of FinanceMr. Matt Whitmire

Vice President of AccountingMs. Maria Dobek

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dobek Maria	Vice President, Accounting	May 11 '26	Sale	14.17	2,038	28,878	32,270	May 13 08:00 PM
ANDY MEYER	Former Affiliate	Apr 13 '26	Proposed Sale	15.05	1,877	28,246		Apr 13 04:05 PM
ZACHARIAH A MCIVER	Former Officer	Apr 02 '26	Proposed Sale	14.65	74,802	1,095,761		Apr 02 04:02 PM
ANDY MEYER	Former Affiliate	Jan 26 '26	Proposed Sale	14.55	178,767	2,601,113		Jan 26 04:20 PM
ANDY MEYER	Former Affiliate	Jan 23 '26	Proposed Sale	14.72	118,122	1,738,390		Jan 23 04:08 PM
Meyer Andrew Hollman	Chief Business Officer	Jan 02 '26	Sale	13.73	1,879	25,799	83,095	Jan 02 09:00 PM
DiRaimondo Thomas	Chief Scientific Officer	Jan 02 '26	Sale	13.73	2,505	34,394	124,425	Jan 02 09:00 PM
Campbell David Alan	President and CEO	Jan 02 '26	Sale	13.73	8,072	110,829	284,982	Jan 02 09:00 PM
Winter Charles M.	Chief Technical Officer	Jan 02 '26	Sale	13.73	2,401	32,966	77,721	Jan 02 09:00 PM
McIver Zachariah	Chief Medical Officer	Jan 02 '26	Sale	13.73	2,714	37,263	23,286	Jan 02 09:00 PM
Dobek Maria	Vice President, Accounting	Jan 02 '26	Sale	13.73	1,462	20,073	15,373	Jan 02 09:00 PM
BYRON C ROBINSON	Officer	Dec 15 '25	Proposed Sale	15.50	16,666	258,366		Dec 15 04:06 PM
BYRON C ROBINSON	Officer	Dec 08 '25	Proposed Sale	16.52	50,000	826,000		Dec 08 04:42 PM
Meyer Andrew Hollman	Chief Business Officer	Dec 01 '25	Option Exercise	10.59	3,333	35,296	88,307	Dec 03 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Dec 01 '25	Sale	32.98	3,333	109,929	84,974	Dec 03 08:00 PM
BYRON C ROBINSON	Officer	Dec 02 '25	Proposed Sale	16.38	63,125	1,033,743		Dec 02 05:15 PM
ANDREW MEYER	Officer	Dec 01 '25	Proposed Sale	34.09	3,333	113,622		Dec 01 04:20 PM
Meyer Andrew Hollman	Chief Business Officer	Nov 14 '25	Option Exercise	10.59	3,333	35,296	88,307	Nov 14 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Nov 14 '25	Sale	30.00	3,333	99,990	84,974	Nov 14 08:00 PM
ANDREW MEYER	Officer	Nov 14 '25	Proposed Sale	27.46	3,333	91,524		Nov 14 04:24 PM
Meyer Andrew Hollman	Chief Business Officer	Oct 28 '25	Option Exercise	6.76	16,665	112,689	98,804	Oct 30 08:00 PM
Meyer Andrew Hollman	Chief Business Officer	Oct 28 '25	Sale	30.06	16,665	500,987	82,139	Oct 30 08:00 PM
ANDREW MEYER	Officer	Oct 28 '25	Proposed Sale	27.35	16,665	455,788		Oct 28 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JANX

Janux Therapeutics Inc

Upgrade your Finviz experience